MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer

Abstract

Prostate cancer is a condition commonly associated with men worldwide. Androgen deprivation therapy remains one of the targeted therapies. However, after some years, there is biochemical recurrence and metastatic progression into castration-resistant prostate cancer (CRPC). CRPC cases are treated with second-line androgen deprivation therapy, after which, these CRPCs transdifferentiate to form neuroendocrine prostate cancer (NEPC), a highly aggressive variant of CRPC. NEPC arises via a reversible transdifferentiation process, known as neuroendocrine differentiation (NED), which is associated with altered expression of lineage markers such as decreased expression of androgen receptor and increased expression of neuroendocrine lineage markers including enolase 2, chromogranin A and synaptophysin. The etiological factors and molecular basis for NED are poorly understood, contributing to a lack of adequate molecular biomarkers for its diagnosis and therapy. Therefore, there is a need to fully understand the underlying molecular basis for this cancer. Recent studies have shown that microRNAs (miRNAs) play a key epigenetic role in driving therapy-induced NED in prostate cancer. In this review, we briefly describe the role of miRNAs in prostate cancer and CRPCs, discuss some key players in NEPCs and elaborate on miRNA dysregulation as a key epigenetic process that accompanies therapy-induced NED in metastatic CRPC. This understanding will contribute to better clinical management of the disease.

Keywords

MicroRNAs / neuroendocrine differentiation / castration-resistant prostate cancer / epigenetics / oncomirs / tumor suppressors / androgen deprivation therapy

References

[1] Rawla P.Epidemiology of Prostate Cancer..World J Oncol2019;10:63-89 PMCID:PMC6497009

[2] Siegel RL,Jemal A.Cancer statistics, 2020..CA Cancer J Clin2020;70:7-30

[3] Ilic D,Jung JH,Zhou Q.Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis..BMJ2018;362:k3519 PMCID:PMC6283370

[4] Bartzatt R.Prostate Cancer: Biology, Incidence, Detection Methods, Treatment Methods, and Vaccines..Curr Top Med Chem2020;20:847-54

[5] Nevedomskaya E,Haendler B.Recent Advances in Prostate Cancer Treatment and Drug Discovery..Int J Mol Sci2018;19:1359 PMCID:PMC5983695

[6] Lipianskaya J,Chen CJ,Squires J.Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation..Asian J Androl2014;16:541-4 PMCID:PMC4104077

[7] Li Q,Zhang Y.Molecular aspects of prostate cancer with neuroendocrine differentiation..Chin J Cancer Res2016;28:122-9 PMCID:PMC4779763

[8] Aggarwal R,Alumkal JJ,Feng FY.Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study..J Clin Oncol2018;36:2492-503 PMCID:PMC6366813

[9] Lee GT,Kim WT,Palapattu G.TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer..PLoS One2019;14:e0213488 PMCID:PMC6752758

[10] Beltran H,Park K,Sboner A.Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets..Cancer Discov2011;1:487 PMCID:PMC3290518

[11] Derlin T,Lafos M,von Klot CAJ.Neuroendocrine differentiation and response to PSMA-targeted radioligand therapy in advanced metastatic castration-resistant prostate cancer: a single-center retrospective study..J Nucl Med2020;

[12] Fraser JA,Tazayoni S,Poole AV.hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen..Sci Rep2019;9:19076 PMCID:PMC6911083

[13] Gupta K.Neuroendocrine differentiation in prostate cancer: key epigenetic players..Translat Cancer Res2017;6:S104-8 PMCID:PMC6320222

[14] Parimi V,Poropatich K.Neuroendocrine differentiation of prostate cancer: a review..Am J Clin Exp Urol2014;2:273-85 PMCID:PMC4297323

[15] Borrego-Diaz E,Azizov V,Reyes R.A potential regulatory loop between Lin28B:miR212 in androgen-independent prostate cancer..Int J Oncol2014;45:2421-9 PMCID:PMC4215582

[16] Chen R,Gleave M.Molecular model for neuroendocrine prostate cancer progression..BJU Int2018;122:560-70

[17] Huang YH,Huang JT.Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms..Asian J Androl2019;21:291-5 PMCID:PMC6498729

[18] Hsu TI,Lee KH,Chen CS.MicroRNA-18a is elevated in prostate cancer and promotes tumorigenesis through suppressing STK4 in vitro and in vivo..Oncogenesis2014;3:e99 PMCID:PMC4007194

[19] Bidarra D,Barros-Silva D,Moreira-Barbosa C.Circulating microRNAs as biomarkers for prostate cancer detection and metastasis development prediction..Front Oncol2019;9:900 PMCID:PMC6749029

[20] Luu HN,Sorensen KD,Kumar N.miRNAs associated with prostate cancer risk and progression..BMC Urol2017;17:18 PMCID:PMC5359825

[21] Crea F,Ci X,Pikor L.The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer..Epigenomics2016;8:721-31

[22] Sun Y,Huang J.Neuroendocrine differentiation in prostate cancer..Am J Transl Res2009;1:148-62 PMCID:PMC2776313

[23] Mizokami A,Konaka H,Kadono Y.Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice..Asian J Androl2017;19:143-8 PMCID:PMC5312209

[24] Zhang D,Li X,Tang DG.Prostate luminal progenitor cells in development and cancer..Trends cancer2018;4:769-83 PMCID:PMC6212301

[25] Stoyanova T,Drake JM,Armstrong AJ.Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells..Proc Natl Acad Sci U S A2013;110:20111-6 PMCID:PMC3864278

[26] Aggarwal R,Small EJ.Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes..J Natl Compr Canc Netw2014;12:719-26

[27] Arisan ED,Freitas IL,Keskin B.Upregulated Wnt-11 and miR-21 expression trigger epithelial mesenchymal transition in aggressive prostate cancer cells..Biology (Basel)2020;9: PMCID:PMC7150874

[28] Ceder Y,Culig Z,Tomlins S.The molecular evolution of castration-resistant prostate cancer..Eur Urol Focus2016;2:506-13

[29] Czyrnik ED,Dankert JT.The regulation of HAS3 by miR-10b and miR-29a in neuroendocrine transdifferentiated LNCaP prostate cancer cells..Biochem Biophys Res Commun2020;523:713-8

[30] Hsu EC,Bermudez A,Aslan M.Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1..Proc Natl Acad Sci U S A2020;117:2032-42 PMCID:PMC6994991

[31] Aparicio AM,Tapia EL,Chen HC.Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers..Clin Cancer Res2016;22:1520-30 PMCID:PMC4794379

[32] Patel GK,Tripathi M.Neuroendocrine differentiation of prostate cancer-an intriguing example of tumor evolution at play..Cancers (Basel)2019;11: PMCID:PMC6826557

[33] Conteduca V,Eng KW,Sigouros M.Clinical features of neuroendocrine prostate cancer..Eur J Cancer2019;121:7-18 PMCID:PMC6803064

[34] Kranitz N,Kocsis K.Neuroendocrine cancer of the prostate..Pathol Oncol Res2019;

[35] Bjorkman M,Nees M.Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes..Epigenomics2010;2:683-9

[36] Blute ML Jr.,Jarrard DF.The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications..Curr Opin Urol2015;25:83-8 PMCID:PMC5526656

[37] Albany C,Aparicio AM,Yellapragada S.Epigenetics in prostate cancer..Prostate Cancer2011;2011:580318 PMCID:PMC3236424

[38] Diaw L,Gillespie JW.Prostate cancer epigenetics: a review on gene regulation..Gene Regul Syst Bio2007;1:313-25 PMCID:PMC2759139

[39] Jerónimo C,Bjartell A,Catto JWF.Epigenetics in prostate cancer: biologic and clinical relevance..Eur Urol2011;60:753-66

[40] Nakayama T,Suzuki H,Sekita N.Epigenetic regulation of androgen receptor gene expression in human prostate cancers..Lab Invest2000;80:1789-96

[41] Davies A,Selth LA.The epigenetic and transcriptional landscape of neuroendocrine prostate cancer..Endocr Relat Cancer2020;27:R35-50

[42] Greenberg MVC.The diverse roles of DNA methylation in mammalian development and disease..Nat Rev Mol Cell Biol2019;20:590-607

[43] Park JW,Sheu KM,Balanis NG.Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage..Science2018;362:91-5 PMCID:PMC6414229

[44] McMcCabe MT,Day ML.Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway..Cancer Res2005;65:3624-32

[45] Smith BA,Nanjundiah A,Tsai BL.A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers..Cell Rep2018;24:3353-3366.e5 PMCID:PMC6382070

[46] Suh SO,Zaman MS,Yamamura S.MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer..Carcinogenesis2011;32:772-8 PMCID:PMC3086703

[47] Logothetis CJ,Maity SN,Aparicio A.Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer..Cancer Discov2013;3:849-61 PMCID:PMC3926428

[48] Bannister AJ.Regulation of chromatin by histone modifications..Cell Res2011;21:381-95 PMCID:PMC3193420

[49] Vlachostergios PJ.Targeting neuroendocrine prostate cancer: molecular and clinical perspectives..Front Oncol2015;5:6 PMCID:PMC4313607

[50] Varambally S,Mani RS,Wang X.Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer..Science2008;322:1695-9 PMCID:PMC2684823

[51] Cannell IG,Bushell M.How do microRNAs regulate gene expression?.Biochem Soc Trans2008;36:1224-31

[52] Cozar JM,Rodriguez-Martinez A,Vazquez-Alonso F.The role of miRNAs as biomarkers in prostate cancer..Mutat Res2019;781:165-74

[53] Ma G,Wu Y,Pan F.LncRNAs and miRNAs: potential biomarkers and therapeutic targets for prostate cancer..Am J Transl Res2016;8:5141-50 PMCID:PMC5209471

[54] Baumann V.miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents..Future med chem2014;6:1967-84 PMCID:PMC4417715

[55] DeVere White RW,Tepper CG.MicroRNAs and their potential for translation in prostate cancer..Urol Oncol2009;27:307-11 PMCID:PMC2761743

[56] Vanacore D,Rossetti S,D’Aniello C.Micrornas in prostate cancer: an overview..Oncotarget2017;8:50240-51 PMCID:PMC5564846

[57] Calin GA.MicroRNA signatures in human cancers..Nat Rev Cancer2006;6:857-66

[58] Heneghan HM,Kerin MJ.MiRNAs as biomarkers and therapeutic targets in cancer..Curr Opin Pharmacol2010;10:543-50

[59] Svoronos AA,Slack FJ.OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer..Cancer Res2016;76:3666-70 PMCID:PMC4930690

[60] Terry S.The many faces of neuroendocrine differentiation in prostate cancer progression..Front Oncol2014;4:60 PMCID:PMC3971158

[61] Zhang Y,Zhou T,Hulsurkar M.Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers..Nat Commun2018;9:4080 PMCID:PMC6172226

[62] Jiao L,Xu C,Li Y.miR-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence..J Cell Physiol2014;229:834-44

[63] Seibert JK,Quintavalle C,Terracciano L.A role for the dehydrogenase DHRS7 (SDR34C1) in prostate cancer..Cancer Med2015;4:1717-29 PMCID:PMC4673999

[64] Romanuik TL,Morozova O,Marra MA.LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer..BMC Med Genomics2010;3:43 PMCID:PMC2956710

[65] Liang H,Hullinger RL,Andrisani OM.Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b~25..Exp Cell Res2014;320:188-99 PMCID:PMC3947575

[66] Ambs S,Yi M,Howe TM.Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer..Cancer Res2008;68:6162-70 PMCID:PMC2597340

[67] Hudson RS,Esposito D,Starks AM.MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer..Oncogene2013;32:4139-47 PMCID:PMC3530025

[68] Kiener M,Krebs M,Klima I.miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo..BMC Cancer2019;19:627 PMCID:PMC6593572

[69] Taylor BS,Hieronymus H,Xiao Y.Integrative genomic profiling of human prostate cancer..Cancer cell2010;18:11-22 PMCID:PMC3198787

[70] Zheng C,Li J.MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2..Med Oncol2012;29:815-22

[71] Galardi S,Giorda E,Frajese GV.miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1..J Biol Chem2007;282:23716-24

[72] Goto Y,Nishikawa R,Kato M.MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker..Br J Cancer2015;113:1055-65 PMCID:PMC4651127

[73] Shao N,Zhang J.miR-221-5p enhances cell proliferation and metastasis through post-transcriptional regulation of SOCS1 in human prostate cancer..BMC Urol2018;18:14 PMCID:PMC5836432

[74] Nam RK,Amemiya Y,Romero JM.MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells..Oncotarget2018;9:19159-76 PMCID:PMC5922385

[75] Silverstein AM,Davis AJ.Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits..Proc Natl Acad Sci U S A2002;99:4221-6 PMCID:PMC123629

[76] Damodaran C,Papu John AM,Kolluru V.miR-301a expression: A prognostic marker for prostate cancer..Urol Oncol2016;34:336.e13-20 PMCID:PMC4967401

[77] Bhagirath D,Patel N,Lui B.MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer..Oncogene Forthcoming2020;

[78] Chen F,Bai J,Xi Y.Role of RUNX3 in suppressing metastasis and angiogenesis of human prostate cancer..PLoS one2014;9:e86917 PMCID:PMC3901713

[79] Kolluru V,Tyagi A,Ankem M.miR-301a expression: Diagnostic and prognostic marker for prostate cancer..Urol Oncol2018;36:503.e9-503.e15

[80] Shan J,Al-Kowari MK,Al-Rumaihi K.Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer..Cell Death Discov.2019;5:139[PMC6768854: [DOI: 10.1038/s41420-019-0218-y] PMCID:PMC6768854

[81] Saini S,Shahryari V,Yamamura S.miRNA-708 control of CD44(+) prostate cancer-initiating cells..Cancer Res2012;72:3618-30

[82] Iczkowski KA.Cell adhesion molecule CD44: its functional roles in prostate cancer..Am J transl res2010;3:1-7 PMCID:PMC2981422

[83] Shi XB,Yang J,Zhao J.An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells..Proc Natl Acad Sci U S A2007;104:19983-8 PMCID:PMC2148409

[84] Lo UG,Hsieh JT.The role of microRNAs in prostate cancer progression..Translational andrology and urology2013;2:228-41 PMCID:PMC4708182

[85] Bonci D,Patrizii M,Cannistraci A.A microRNA code for prostate cancer metastasis..Oncogene2016;35:1180-92 PMCID:PMC4803473

[86] Bonci D,Musumeci M,Giuffrida R.The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities..Nat Med2008;14:1271-7

[87] Lin Y,Hiipakka RA,Xiang J.Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage..Cell Res2007;17:531-6

[88] Cao Z,Xu Y,Ji J.Differential Expression and Prognostic Value of Cytoplasmic and Nuclear Cyclin D1 in Prostate Cancer..Biomed Res Int2020;2020:1692658 PMCID:PMC7281841

[89] Razdan A,Roberts TL.Role of MicroRNAs in Treatment Response in Prostate Cancer..Curr Cancer Drug Targets2018;18:929-44 PMCID:PMC6463399

[90] Shi R,Yang T,Tian Y.Effects of miR-200c on the migration and invasion abilities of human prostate cancer Du145 cells and the corresponding mechanism..Front Med2014;8:456-63

[91] Peinado H,Cano A.Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?.Nat Rev Cancer2007;7:415-28

[92] Kong D,Wang Z,Ahmad A.miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells..Stem Cells2009;27:1712-21 PMCID:PMC3400149

[93] Vallejo DM,Dominguez M.Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells..EMBO J2011;30:756-69 PMCID:PMC3041954

[94] Santagata S,Riva A,Hofer MD.JAGGED1 expression is associated with prostate cancer metastasis and recurrence..Cancer Res2004;64:6854-7

[95] Hsieh IS,Tsai YT,Lu PJ.MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway..Carcinogenesis2013;34:530-8

[96] Li Y,Zhang M,Liu X.LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion..Cancer research2009;69:3332-8 PMCID:PMC3182465

[97] Yang X,Terry S,Bemis DL.Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells..Oncogene2006;25:3436-44 PMCID:PMC2630384

[98] Pal SK,He M,Kraft K.Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC)..Cancer2018;124:1216-24

[99] Nouri M,Caradec J,Li N.Transient Sox9 expression facilitates resistance to androgen-targeted therapy in prostate cancer..Clin Cancer Res2020;

[100] Kosaka T,Yoshimine S,Daimon T.The prognostic significance of OCT4 expression in patients with prostate cancer..Human Pathol2016;51:1-8

[101] Okato A,Kurozumi A,Kojima S.Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in prostate cancer..Int J Oncol2016;49:111-22 PMCID:PMC4902064

[102] Bhatnagar N,Padi SK,Tang MS.Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells..Cell Death Dis2010;1:e105 PMCID:PMC3004480

[103] Fuse M,Enokida H,Yoshino H.Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer..J Hum Genet2012;57:691-9

[104] Gandellini P,Longoni N,Binda M.miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon..Cancer Res2009;69:2287-95

[105] Wu D,Gregory CW,Wescott GG.Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer..Cancer Res2002;62:2423-9

[106] Boll K,Kasack K,Kretzschmar AK.MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma..Oncogene2013;32:277-85

[107] Diamandis EP,Luo LY,Obiezu CV.The new human kallikrein gene family: implications in carcinogenesis..Trends Endocrinol Metab2000;11:54-60

[108] Ribas J.The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer..Cell Cycle2010;9:923-9 PMCID:PMC3462654

[109] Li T,Sha J,Huang Y.MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells..Biochem Biophys Res Commun2009;383:280-5

[110] Reis ST,Antunes AA,Dip N.miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer..BMC Urol2012;12:14 PMCID:PMC3431982

[111] Shi GH,Yao XD,Dai B.Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells..Acta Pharmacol Sin2010;31:867-73 PMCID:PMC4007720

[112] Teply BA.Chemotherapy options in castration-resistant prostate cancer..Indian J Urol2016;32:262-70 PMCID:PMC5054655

[113] Sun T,Chen S,Pomerantz M.The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer..Prostate2012;72:1093-103 PMCID:PMC3810996

[114] Hannafon BN,Calloway CL,Zhang R.miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study..BMC Cancer2019;19:642 PMCID:PMC6599331

[115] Ishteiwy RA,Dykxhoorn DM.The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells..PLoS One2012;7:e52106 PMCID:PMC3530545

[116] Kobayashi T,Shimizu Y,Maeno A.Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo..Mol Endocrinol2010;24:722-34 PMCID:PMC5417531

[117] Knight-Krajewski S,Liu Y,Faysal JM.Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21CIP1 levels in androgen-independent human prostate cancer cells..Oncogene2004;23:5513-22

[118] Yamamura S,Majid S,Ueno K.MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells..PLoS One2012;7:e29722 PMCID:PMC3250472

[119] Chalanqui MJ,Dunne NJ.MiRNA 34a: a therapeutic target for castration-resistant prostate cancer..Expert Opin Ther Targets2016;20:1075-85

[120] Kojima K,Nozawa Y,Ito M.MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms..Prostate2010;70:1501-12

[121] Simon RA,Huang LS,Yao JL.CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers..Hum Pathol2009;40:252-8

[122] Palapattu GS,Silvers CR,Williams K.Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer..Prostate2009;69:787-98

[123] Liu C,Liu B,Calhoun-Davis T.The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44..Nat Med2011;17:211-5 PMCID:PMC3076220

[124] Xu B,Wang X,Shao N.MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer..Prostate2012;72:1171-8

[125] Lin SL,Chang D.Loss of mir-146a function in hormone-refractory prostate cancer..RNA2008;14:417-24 PMCID:PMC2248249

[126] Kanwal R,Liu X,Gupta S.MicroRNAs in prostate cancer: Functional role as biomarkers..Cancer Lett2017;407:9-20

[127] Kim WT.MicroRNAs in prostate cancer..Prostate Int2013;1:3-9 PMCID:PMC3821523

[128] Xu B,Niu X,Jiang L.Hsa-miR-146a-5p modulates androgen-independent prostate cancer cells apoptosis by targeting ROCK1..Prostate2015;75:1896-903

[129] Wang L,Tan W,Zhang L.MiR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition..Oncotarget2015;6:35978-90 PMCID:PMC4742155

[130] Li T,Li YH,Chen YY.miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer..J Urol2012;187:1466-72

[131] Zedan AH,Assenholt J,Hansen TF.Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer..Sci Rep2020;10:227 PMCID:PMC6959345

[132] Nam RK,Benatar T,Stojcic-Bendavid J.Identification and validation of a five microRNA signature predictive of prostate cancer recurrence and metastasis: a cohort study..J Cancer2015;6:1160-71 PMCID:PMC4615353

[133] Andersen GB.Circulating miRNAs as biomarker in cancer..Recent Results Cancer Res2020;215:277-98

[134] Yeung ML.MicroRNAs and cancer therapeutics..Pharm Res2011;28:3043-9 PMCID:PMC3404888

[135] Ahmadzada T,McKenzie DR.Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer..Biophys Rev2018;10:69-86 PMCID:PMC5803180

[136] Lam JK,Zhang Y.siRNA Versus miRNA as Therapeutics for Gene Silencing..Mol Ther Nucleic Acids2015;4:e252 PMCID:PMC4877448

[137] Fabris L,Chinnaiyan AM,Sorensen KD.The potential of microRNAs as prostate cancer biomarkers..Eur Urol2016;70:312-22 PMCID:PMC4927364

[138] Ishida M.miRNA-Based Therapeutic Strategies..Curr Anesthesiol Rep2013;1:63-70 PMCID:PMC3601800

[139] Li C,Coukos G.Therapeutic microRNA strategies in human cancer..AAPS J2009;11:747-57 PMCID:PMC2782079

[140] Rothschild SI.microRNA therapies in cancer..Mol Cell Ther2014;2:7 PMCID:PMC4452061

[141] Lin CJ,Hsieh JT.The regulatory pathways leading to stem-like cells underlie prostate cancer progression..Asian J Androl2019;21:233-40 PMCID:PMC6498735

[142] Lin PC,Banerjee S,Mosquera JM.Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression..Cancer Res2013;73:1232-44 PMCID:PMC3563734